<?xml version="1.0" encoding="UTF-8"?>

<rss version="2.0"
  xmlns:content="http://purl.org/rss/1.0/modules/content/"
  xmlns:dc="http://purl.org/dc/elements/1.1/"
  xmlns:media="http://search.yahoo.com/mrss/"
  xmlns:atom="http://www.w3.org/2005/Atom"
  xmlns:georss="http://www.georss.org/georss">

  <channel>
    <title>
      <![CDATA[  the cedar ledge  ]]>
    </title>
    <link> https://jacobzelko.com </link>
    <description>
      <![CDATA[  Jacob S. Zelko&#39;s personal website  ]]>
    </description>
    <atom:link
      href="https://jacobzelko.com/feed.xml"
      rel="self"
      type="application/rss+xml" />


<item>
  <title>
    <![CDATA[  COVID-19 and the other pandemic: populations made vulnerable by systemic inequity  ]]>
  </title>
  <link> https://jacobzelko.com/09082022132448-covid-systemic-inequity/index.html </link>
  <guid> https://jacobzelko.com/09082022132448-covid-systemic-inequity/index.html </guid>
  <description>
    <![CDATA[  How the COVID pandemic lead to highlighting vulnerable populations introduced by systemic inequity for healthcare  ]]>
  </description>  
  
  <content:encoded>
    <![CDATA[  
<h1>COVID-19 and the other pandemic: populations made vulnerable by systemic inequity</h1>
<p><strong>Date:</strong> September 8 2022</p>
<p><strong>Summary:</strong> How the COVID pandemic lead to highlighting vulnerable populations introduced by systemic inequity for healthcare</p>
<p><strong>Keywords:</strong> ##bibliography #inequity #minorities #covid19 #pandemic #vulnerable  #archive</p>
<h1>Bibliography</h1>
<p>D. M. Gray, A. Anyane-Yeboa, S. Balzora, R. B. Issaka, and F. P. May, &quot;COVID-19 and the other pandemic: populations made vulnerable by systemic inequity,&quot; Nat Rev Gastroenterol Hepatol, vol. 17, no. 9, pp. 520–522, Sep. 2020, doi: 10.1038/s41575-020-0330-8.</p>
<h1>Table of Contents</h1>
<div class="franklin-toc"><ol><li><ol><li>Reading Motivation</li><li>Vulnerable Population Examples</li></ol></li><li>How To Cite</li><li>References:</li><li>Discussion: </li></ol></div>
<h3 id="reading_motivation">Reading Motivation</h3>
<p>I examined this paper to learn more about vulnerabilities posed to minority and vulnerable populations. I focused less on pandemic-related risks and more on examples of problems posed to minority populations.</p>
<h3 id="vulnerable_population_examples">Vulnerable Population Examples</h3>
<p>Intersectional vulnerable populations &#40;e.g. those living with disability, poverty conditions, or racial minority, etc.&#41; face even more perils to their already vulnerable state.</p>
<ul>
<li><p>African Americans have the highest mortality from colorectal cancer. &#40;3, 4&#41;</p>
</li>
</ul>
<pre><code class="language-julia">- Diagnosed at younger ages 
- Intersectionally, African Americans who are poor, uninsured, and/or geographically isolated are less likely to get screening tests 
	- Less likely to receive treatment for advanced disease</code></pre>
<ul>
<li><p>Hispanics or Latinos are disproportionately affected by SDOH factors. &#40;5&#41;</p>
</li>
</ul>
<pre><code class="language-julia">- Have highest incidence of nonalcoholic fatty liver disease</code></pre>
<ul>
<li><p>Native American reservations lack low number of ICU hospital beds. &#40;8&#41;</p>
</li>
</ul>
<pre><code class="language-julia">- Indian Health Services only had limited ability to help COVID-19 patients.</code></pre>
<ul>
<li><p>Minorities are over-represented as and in: &#40;9&#41;</p>
</li>
</ul>
<pre><code class="language-julia">- Essential workers 
- Poor and overcrowded housing
- Could be impossible to adhere to COVID-19 safety policies</code></pre>
<h2 id="how_to_cite">How To Cite</h2>
<p>Zelko, Jacob. <em>COVID-19 and the other pandemic: populations made vulnerable by systemic inequity</em>. <a href="https://jacobzelko.com/09082022132448-covid-systemic-inequity">https://jacobzelko.com/09082022132448-covid-systemic-inequity</a>. September 8 2022.</p>
<h2 id="references">References:</h2>
<h2 id="discussion">Discussion: </h2>
<script src="https://giscus.app/client.js"
    data-repo="TheCedarPrince/thecedarprince.github.io"
    data-repo-id="R_kgDOHRFrHA"
    data-category="General"
    data-category-id="DIC_kwDOHRFrHM4CPGIX"
    data-mapping="url"
    data-reactions-enabled="1"
    data-emit-metadata="0"
    data-input-position="top"
    data-theme="dark_dimmed"
    data-lang="en"
    data-loading="lazy"
    crossorigin="anonymous"
    async>
</script>
 ]]>
  </content:encoded>
    
  <pubDate>Thu, 08 Sep 2022 00:00:00 +0000</pubDate>  
  
  
  <atom:author>
    <atom:name>Jacob Zelko</atom:name>
  </atom:author>
        
</item>

<item>
  <title>
    <![CDATA[  LGBTQ Populations: Psychologically Vulnerable Communities in the COVID-19 Pandemic  ]]>
  </title>
  <link> https://jacobzelko.com/09082022132720-lgbtq-psychologically-vulnerable/index.html </link>
  <guid> https://jacobzelko.com/09082022132720-lgbtq-psychologically-vulnerable/index.html </guid>
  <description>
    <![CDATA[  A brief report on the risks encountered by LGBTQ communities as a result of the COVID-19 pandemic  ]]>
  </description>  
  
  <content:encoded>
    <![CDATA[  
<h1>LGBTQ Populations: Psychologically Vulnerable Communities in the COVID-19 Pandemic</h1>
<p><strong>Date:</strong> September 8 2022</p>
<p><strong>Summary:</strong> A brief report on the risks encountered by LGBTQ communities as a result of the COVID-19 pandemic</p>
<p><strong>Keywords:</strong> ##bibliography #lgbtq #pandemic #covid19 #mental #health #vulnerable  #archive</p>
<h1>Bibliography</h1>
<p>J. P. Salerno, N. D. Williams, and K. A. Gattamorta, &quot;LGBTQ Populations: Psychologically Vulnerable Communities in the COVID-19 Pandemic,&quot; p. 4.</p>
<h1>Table of Contents</h1>
<div class="franklin-toc"><ol><li><ol><li>Reading Motivation</li><li>LGBTQ Risks</li></ol></li><li>How To Cite</li><li>References:</li><li>Discussion: </li></ol></div>
<h3 id="reading_motivation">Reading Motivation</h3>
<p>I examined this paper at the time to find out more about vulnerabilities posed to LGBTQ populations. I was less interested in the pandemic&#39;s potential impacts on these populations although this paper did have many thoughts on the topic.</p>
<h3 id="lgbtq_risks">LGBTQ Risks</h3>
<p>The LGBTQ community faces significant mental health disparities compared to heterosexual, cisgender populations &#40;Plöderl &amp; Tremblay, 2015; Price-Feeney, Green, &amp; Dorison, 2020; Russell &amp; Fish, 2016&#41;</p>
<p>People of color within the LGBTQ community are at greater risk for social inequality &#40;Baams, Wilson, &amp; Russell, 2019; Conron &amp; Wilson, 2019; Movement Advancement Project &amp; SAGE, 2017; Morton et al., 2018; Whittington et al., 2020&#41;.</p>
<p>Intersectional LGBTQ youth populations &#40;e.g. stratified by race, ethnicity, immigration status, poverty conditions, etc.&#41; generally engage more often with school mental health services &#40;Ali et al., 2019; Golberstein, Wen, &amp; Miller, 2020&#41;.</p>
<h2 id="how_to_cite">How To Cite</h2>
<p>Zelko, Jacob. <em>LGBTQ Populations: Psychologically Vulnerable Communities in the COVID-19 Pandemic</em>. <a href="https://jacobzelko.com/09082022132720-lgbtq-psychologically-vulnerable">https://jacobzelko.com/09082022132720-lgbtq-psychologically-vulnerable</a>. September 8 2022.</p>
<h2 id="references">References:</h2>
<h2 id="discussion">Discussion: </h2>
<script src="https://giscus.app/client.js"
    data-repo="TheCedarPrince/thecedarprince.github.io"
    data-repo-id="R_kgDOHRFrHA"
    data-category="General"
    data-category-id="DIC_kwDOHRFrHM4CPGIX"
    data-mapping="url"
    data-reactions-enabled="1"
    data-emit-metadata="0"
    data-input-position="top"
    data-theme="dark_dimmed"
    data-lang="en"
    data-loading="lazy"
    crossorigin="anonymous"
    async>
</script>
 ]]>
  </content:encoded>
    
  <pubDate>Thu, 08 Sep 2022 00:00:00 +0000</pubDate>  
  
  
  <atom:author>
    <atom:name>Jacob Zelko</atom:name>
  </atom:author>
        
</item>

<item>
  <title>
    <![CDATA[  Intellectual and Developmental Disability and COVID-19 Case-fatality Trends: TriNetX Analysis  ]]>
  </title>
  <link> https://jacobzelko.com/07192020022823-intellectual-trinetx-analysis/index.html </link>
  <guid> https://jacobzelko.com/07192020022823-intellectual-trinetx-analysis/index.html </guid>
  <description>
    <![CDATA[  Intellectual and developmental disability and association with COVID-19 fatalities  ]]>
  </description>  
  
  <content:encoded>
    <![CDATA[  
<h1>Intellectual and Developmental Disability and COVID-19 Case-fatality Trends: TriNetX Analysis</h1>
<p><strong>Date:</strong> July 19 2020</p>
<p><strong>Summary:</strong> Intellectual and developmental disability and association with COVID-19 fatalities</p>
<p><strong>Keywords:</strong> ##bibliography #covid19 ##pandemic #idd #intellectual #disability #archive</p>
<h1>Bibliography</h1>
<p>M. A. Turk, S. D. Landes, M. K. Formica, and K. D. Goss, &quot;Intellectual and developmental disability and COVID-19 case-fatality trends: TriNetX analysis,&quot; Disability and Health Journal, p. 100942, May 2020, doi: 10.1016/j.dhjo.2020.100942.</p>
<h1>Table of Contents</h1>
<div class="franklin-toc"><ol><li><ol><li>Data Methods</li></ol></li><li>How To Cite</li><li>References</li><li>Discussion: </li></ol></div>
<p>The central hypotheses of this paper are:</p>
<ol>
<li><p>IDD persons have higher prevalence of conditions associated with higher COVID-19 morbidity and mortality outcomes</p>
</li>
<li><p>Case-fatality rate would be higher for COVID19 individuals with IDD than without IDD.</p>
</li>
</ol>
<h3 id="data_methods">Data Methods</h3>
<p>COVID-19 patients were defined as those with either a COVID-19 diagnosis code or a positive SARS-CoV-2 laboratory test result since January 20, 2020. Patients were categorized as those with and without diagnosed developmental disability, including intellectual disability &#40;F70-79&#41;, cerebral palsy &#40;G80&#41;, Down syndrome &#40;Q90&#41;, and other developmental disabilities &#40;F80-89, Q91-99&#41;.</p>
<p>Documentation was provided for comorbidities related to risk for severe outcomes with COVID-19 up to the date of the first COVID-19 documentation. Trends in number of cases, number of deaths, and case-fatality rates were compared between COVID19 patients with IDD and without IDD. Age distributions for number of cases and number of deaths were computed for both patient groups. Deaths occurring within 30 days of the date of first COVID-19 documentation in the EMR were identified and used to calculate case-fatality rates and 95&#37; confidence intervals. Age groups were selected based upon the knowledge that COVID-19 rates are substantially lower among children, &#91;1&#93; and that a disproportionately lower percent of adults with IDD live into older age. &#91;2&#93;</p>
<p>We excluded patients with diagnosis codes of other specified viral infection &#40;ICD-9 code: 097.89&#41; or suspected exposure to other biologic agents &#40;ICD-10 code: Z03.818&#41; during the same timeframe</p>
<h2 id="how_to_cite">How To Cite</h2>
<p>Zelko, Jacob. <em>Intellectual and Developmental Disability and COVID-19 Case-fatality Trends: TriNetX Analysis</em>. <a href="https://jacobzelko.com/07192020022823-intellectual-trinetx-analysis">https://jacobzelko.com/07192020022823-intellectual-trinetx-analysis</a>. July 19 2020.</p>
<h2 id="references">References</h2>
<p>&#91;1&#93; CDC, “Severe outcomes among patients with coronavirus disease 2019 &#40;COVID-19&#41;—United States, February 12–March 16, 2020,” MMWR Morb Mortal Wkly Rep, vol. 69, no. 12, pp. 343–346, 2020.</p>
<p>&#91;2&#93; S. Landes, J. Stevens, and M. Turk, “Heterogeneity in age at death for adults with developmental disability,” J. Intellect. Disabil. Res., vol. 63, no. 12, pp. 1482–1487, 2019.</p>
<h2 id="discussion">Discussion: </h2>
<script src="https://giscus.app/client.js"
    data-repo="TheCedarPrince/thecedarprince.github.io"
    data-repo-id="R_kgDOHRFrHA"
    data-category="General"
    data-category-id="DIC_kwDOHRFrHM4CPGIX"
    data-mapping="url"
    data-reactions-enabled="1"
    data-emit-metadata="0"
    data-input-position="top"
    data-theme="dark_dimmed"
    data-lang="en"
    data-loading="lazy"
    crossorigin="anonymous"
    async>
</script>
 ]]>
  </content:encoded>
    
  <pubDate>Sun, 19 Jul 2020 00:00:00 +0000</pubDate>  
  
  
  <atom:author>
    <atom:name>Jacob Zelko</atom:name>
  </atom:author>
        
</item>

<item>
  <title>
    <![CDATA[  TriNet  ]]>
  </title>
  <link> https://jacobzelko.com/07192020013500-trinetx-covid/index.html </link>
  <guid> https://jacobzelko.com/07192020013500-trinetx-covid/index.html </guid>
  <description>
    <![CDATA[  An overview of what the TriNetX COVID-19 research platform is and how it works  ]]>
  </description>  
  
  <content:encoded>
    <![CDATA[  
<h1>TriNet</h1>
<p><strong>Date:</strong> July 18 2020</p>
<p><strong>Summary:</strong> An overview of what the TriNetX COVID-19 research platform is and how it works</p>
<p><strong>Keywords:</strong> ##zettel #covid19 ##pandemic #health #dataset #EMR #archive</p>
<h1>Bibliography</h1>
<p>Not Available</p>
<h1>Table of Contents</h1>
<div class="franklin-toc"><ol><li><ol><li>ICD10 Codes for COVID19 from TriNetX</li><li>LOINC COVID19 Codes</li></ol></li><li>How To Cite</li><li>References</li><li>Discussion: </li></ol></div>
<p>The TriNetX COVID-19 Research Network Platform is a network of EMR data from 42 health care organizations designed to facilitate research related to COVID-19. &#91;1&#93;, &#91;2&#93;</p>
<p>TriNetX provides access to de-identified aggregate EMR data including information such as &#91;1&#93;, &#91;2&#93;:</p>
<ul>
<li><p>Demographics</p>
</li>
<li><p>Diagnoses</p>
</li>
<li><p>Procedures</p>
</li>
<li><p>Medications</p>
</li>
<li><p>Laboratory values</p>
</li>
<li><p>Genomics</p>
</li>
</ul>
<h3 id="icd10_codes_for_covid19_from_trinetx">ICD10 Codes for COVID19 from TriNetX</h3>
<ul>
<li><p>B34.2</p>
</li>
<li><p>B97.29</p>
</li>
<li><p>J12.81</p>
</li>
<li><p>U07.1</p>
</li>
<li><p>U07.2</p>
</li>
</ul>
<h3 id="loinc_covid19_codes">LOINC COVID19 Codes</h3>
<ul>
<li><p>94500-6</p>
</li>
<li><p>94315-9</p>
</li>
<li><p>94309-2</p>
</li>
<li><p>94533-7</p>
</li>
<li><p>94534-5</p>
</li>
<li><p>94559-2</p>
</li>
</ul>
<h2 id="how_to_cite">How To Cite</h2>
<p>Zelko, Jacob. <em>TriNet</em>. <a href="https://jacobzelko.com/07192020013500-trinetx-covid">https://jacobzelko.com/07192020013500-trinetx-covid</a>. July 18 2020.</p>
<h2 id="references">References</h2>
<p>&#91;1&#93; J. Stacey and M. Mehta, “Using EHR data extraction to streamline the clinical trial process,” Clin. Res., vol. 4, pp. 2–7, 2017.</p>
<p>&#91;2&#93; M. Stapff, “Use of electronic health data in clinical development,” Pharm. Ind, vol. 79, no. 2, pp. 204–210, 2017.</p>
<h2 id="discussion">Discussion: </h2>
<script src="https://giscus.app/client.js"
    data-repo="TheCedarPrince/thecedarprince.github.io"
    data-repo-id="R_kgDOHRFrHA"
    data-category="General"
    data-category-id="DIC_kwDOHRFrHM4CPGIX"
    data-mapping="url"
    data-reactions-enabled="1"
    data-emit-metadata="0"
    data-input-position="top"
    data-theme="dark_dimmed"
    data-lang="en"
    data-loading="lazy"
    crossorigin="anonymous"
    async>
</script>
 ]]>
  </content:encoded>
    
  <pubDate>Sat, 18 Jul 2020 00:00:00 +0000</pubDate>  
  
  
  <atom:author>
    <atom:name>Jacob Zelko</atom:name>
  </atom:author>
        
</item>

<item>
  <title>
    <![CDATA[  Could Autism Spectrum Disorders Be A Risk Factor For covid-19?  ]]>
  </title>
  <link> https://jacobzelko.com/07192020034934-asd-risk-factor/index.html </link>
  <guid> https://jacobzelko.com/07192020034934-asd-risk-factor/index.html </guid>
  <description>
    <![CDATA[  Autism Spectrum Disorders as a potential risk factor in COVID-19 outcomes  ]]>
  </description>  
  
  <content:encoded>
    <![CDATA[  
<h1>Could Autism Spectrum Disorders Be A Risk Factor For covid-19?</h1>
<p><strong>Date:</strong> July 18 2020</p>
<p><strong>Summary:</strong> Autism Spectrum Disorders as a potential risk factor in COVID-19 outcomes</p>
<p><strong>Keywords:</strong> ##bibliography #asd #autism #covid19 ##pandemic #archive</p>
<h1>Bibliography</h1>
<p>M. E. de Sousa Lima, L. C. M. Barros, and G. F. Aragão, &quot;Could Autism Spectrum Disorders be a Risk Factor for COVID-19?,&quot; Med Hypotheses, May 2020, doi: 10.1016/j.mehy.2020.109899.</p>
<h1>Table of Contents</h1>
<div class="franklin-toc"><ol><li><ol><li>Cytokine Observations in ASD and COVID19</li></ol></li><li>How To Cite</li><li>References</li><li>Discussion: </li></ol></div>
<blockquote>
<p><strong>NOTE:</strong> The journal medical hypothesis lacks a standard peer review process, but is often utilized to posit ideas quickly.</p>
</blockquote>
<p><strong>Purpose of paper:</strong> consolidate data to support the hypothesis of ASD being a risk for COVID19 like other risks.</p>
<p>Involves several modifications at the genetic and at the immune level &#40;e.g. increases of inflammatorycytokines and abnormal immune response in several levels&#41;. &#91;1&#93; Some are conditions considered risk-factor of symptomatic COVID-19 and its mortality.</p>
<h3 id="cytokine_observations_in_asd_and_covid19">Cytokine Observations in ASD and COVID19</h3>
<p>Initially there is an endogenous immune response in the presence of COVID19. The response is linked to the destruction level of the virus, the patient’s innateresponse, and it determines its inflammation status and symptomatology. &#91;2&#93;</p>
<p>Secretory increases of ACE-2 was correlated with COVID-19 patients &#91;3&#93;. There seem to exist an ACE-2 superexpression leading to a pro-inflammatory state, related to cardiac and pulmonary damage &#91;3&#93; ACE-2 is a regulator in angiotensin-2transformation into angiotensin-&#40;1-7&#41; metabolite. It has inflammatory effects producing vasodilatation, anti-proliferation and apoptosis. This is common to CVD conditions &#91;4&#93;.</p>
<p>Coronavirus also has the characteristic of being neuroinvasive. &#91;5&#93; This characteristic shows via:- Febrile seizures - Encephalitis - Convulsions - Change in mental status Some neurological symptomsfound in COVID-19 patients are non-specific, such as headache, dizziness and confusion. Neurological symptoms were directly related to patients. &#91;6&#93; Thereby, we can hypothesize that its physiopathology might have a strict relation with the nervous system.</p>
<h2 id="how_to_cite">How To Cite</h2>
<p>Zelko, Jacob. <em>Could Autism Spectrum Disorders Be A Risk Factor For covid-19?</em>. <a href="https://jacobzelko.com/07192020034934-asd-risk-factor">https://jacobzelko.com/07192020034934-asd-risk-factor</a>. July 18 2020.</p>
<h2 id="references">References</h2>
<p>&#91;1&#93; H. Ormstad, V. Bryn, O. D. Saugstad, O. Skjeldal, and M. Maes, “Role of the immune system in autism spectrum disorders &#40;ASD&#41;,” CNS Neurol. Disord.-Drug Targets Former. Curr. Drug Targets-CNS Neurol. Disord., vol. 17, no. 7, pp. 489–495, 2018.</p>
<p>&#91;2&#93; Y. Shi et al., “COVID-19 infection: The perspectives on immune responses,” 2020.</p>
<p>&#91;3&#93; Y.-Y. Zheng, Y.-T. Ma, J.-Y. Zhang, and X. Xie, “COVID-19 and the cardiovascular system,” Nat. Rev. Cardiol., vol. 17, no. 5, pp. 259–260, 2020.</p>
<p>&#91;4&#93; A. J. Turner, J. A. Hiscox, and N. M. Hooper, “ACE2: From vasopeptidase to SARS virus receptor,” Trends Pharmacol. Sci., vol. 25, no. 6, pp. 291–294, 2004.</p>
<p>&#91;5&#93; A. A. Asadi-Pooya and L. Simani, “Central nervous system manifestations of COVID-19: A systematic review,” J. Neurol. Sci., p. 116832, 2020.</p>
<p>&#91;6&#93; G. Conde, L. D. Q. Pájaro, I. D. Q. Marzola, Y. R. Villegas, and L. R. M. Salazar, “Neurotropism of SARS-CoV 2: Mechanisms and manifestations,” J. Neurol. Sci., 2020.</p>
<h2 id="discussion">Discussion: </h2>
<script src="https://giscus.app/client.js"
    data-repo="TheCedarPrince/thecedarprince.github.io"
    data-repo-id="R_kgDOHRFrHA"
    data-category="General"
    data-category-id="DIC_kwDOHRFrHM4CPGIX"
    data-mapping="url"
    data-reactions-enabled="1"
    data-emit-metadata="0"
    data-input-position="top"
    data-theme="dark_dimmed"
    data-lang="en"
    data-loading="lazy"
    crossorigin="anonymous"
    async>
</script>
 ]]>
  </content:encoded>
    
  <pubDate>Sat, 18 Jul 2020 00:00:00 +0000</pubDate>  
  
  
  <atom:author>
    <atom:name>Jacob Zelko</atom:name>
  </atom:author>
        
</item>

<item>
  <title>
    <![CDATA[  Hypothesis on Cytokine Dysregulation Worsened by COVID19 for People with ASD  ]]>
  </title>
  <link> https://jacobzelko.com/07102020174816-cytokine-asd-covid19/index.html </link>
  <guid> https://jacobzelko.com/07102020174816-cytokine-asd-covid19/index.html </guid>
  <description>
    <![CDATA[  Loose hypothesis on worsening of cytokine regulation via ASD and COVID19  ]]>
  </description>  
  
  <content:encoded>
    <![CDATA[  
<h1>Hypothesis on Cytokine Dysregulation Worsened by COVID19 for People with ASD</h1>
<p><strong>Date:</strong> July 10 2020</p>
<p><strong>Summary:</strong> Loose hypothesis on worsening of cytokine regulation via ASD and COVID19</p>
<p><strong>Keywords:</strong> ##zettel #asd #autism ##hypothesis #health #mentalhealth #cytokine ##pandemic #covid19 #archive</p>
<h1>Bibliography</h1>
<p>Not Available</p>
<h1>Table of Contents</h1>
<div class="franklin-toc"><ol><li>How To Cite</li><li>References</li><li>Discussion: </li></ol></div>
<blockquote>
<p><strong>Note:</strong> Be careful about conflating correlation with causation.</p>
</blockquote>
<p>I have been closely examining the Hypothalamus Pituitary &#40;HPA&#41; axis and have seen how cytokines directly interact with it. &#91;1&#93; Therefore, since ASD has been correlated with cytokine dysregulation &#91;2&#93;, it can be reasonable to suspect that as coronavirae can also impact cytokine regulation &#91;3&#93;, ASD is a risk factor for COVID19 causing direct problems with the HPA axis leading to multiple downstream issues.</p>
<p>ASD has been correlated with abnormal immune function. This includes:</p>
<ol>
<li><p>Cytokine dysregulation</p>
</li>
<li><p>Inflammation</p>
</li>
<li><p>Presence of autoantibodies</p>
</li>
</ol>
<p>Studies show the presence of anti-brain immunoglobulins in ASD patients. &#91;4&#93; ASD status could also be directly correlated with patients’ cytokine and chemokine levels which cause organ inflammation &#91;2&#93;</p>
<p>There is a second phase resulting in a cytokine storm which particularly affects respiratory epithelium &#91;5&#93;. The storm activates cytokines IL-1-beta, IL-6 and TNFalfa. These activations aggravate respiratory symptoms. These cytokines cause damage to pulmonary microvasculature. It simultaneously affects apoptosis and chemotaxis resulting in decreases of epithelial barriers and alveolar edema <em>Back up references about cytokines</em></p>
<h2 id="how_to_cite">How To Cite</h2>
<p>Zelko, Jacob. <em>Hypothesis on Cytokine Dysregulation Worsened by COVID19 for People with ASD</em>. <a href="https://jacobzelko.com/07102020174816-cytokine-asd-covid19">https://jacobzelko.com/07102020174816-cytokine-asd-covid19</a>. July 10 2020.</p>
<h2 id="references">References</h2>
<p>&#91;1&#93; M. Marmot and R. Wilkinson, Social Determinants of Health, 2nd ed. Oxford University Press, 2006.</p>
<p>&#91;2&#93; A. M. Depino, “Peripheral and central inflammation in autism spectrum disorders,” Mol. Cell. Neurosci., vol. 53, pp. 69–76, 2013.</p>
<p>&#91;3&#93; S. N. J. Korsman, G. U. van Zyl, L. Nutt, M. I. Andersson, and W. Preiser, “Human coronaviruses,” in Virology, Elsevier, 2012, pp. 94–95.</p>
<p>&#91;4&#93; A. Meltzer and J. Van de Water, “The role of the immune system in autism spectrum disorder,” Neuropsychopharmacology, vol. 42, no. 1, pp. 284–298, 2017.</p>
<p>&#91;5&#93; Q. Ye, B. Wang, and J. Mao, “Cytokine storm in COVID-19 and treatment,” J. Infect., 2020.</p>
<h2 id="discussion">Discussion: </h2>
<script src="https://giscus.app/client.js"
    data-repo="TheCedarPrince/thecedarprince.github.io"
    data-repo-id="R_kgDOHRFrHA"
    data-category="General"
    data-category-id="DIC_kwDOHRFrHM4CPGIX"
    data-mapping="url"
    data-reactions-enabled="1"
    data-emit-metadata="0"
    data-input-position="top"
    data-theme="dark_dimmed"
    data-lang="en"
    data-loading="lazy"
    crossorigin="anonymous"
    async>
</script>
 ]]>
  </content:encoded>
    
  <pubDate>Fri, 10 Jul 2020 00:00:00 +0000</pubDate>  
  
  
  <atom:author>
    <atom:name>Jacob Zelko</atom:name>
  </atom:author>
        
</item>

<item>
  <title>
    <![CDATA[  SARS-CoV-2  ]]>
  </title>
  <link> https://jacobzelko.com/03102020051547-sars-cov-2/index.html </link>
  <guid> https://jacobzelko.com/03102020051547-sars-cov-2/index.html </guid>
  <description>
    <![CDATA[  Gives an overview of the 2020 SARS-CoV-2 &#40;COVID19&#41; pandemic and what the disease is.  ]]>
  </description>  
  
  <content:encoded>
    <![CDATA[  
<h1>SARS-CoV-2</h1>
<p><strong>Date:</strong> March 10 2020</p>
<p><strong>Summary:</strong> Gives an overview of the 2020 SARS-CoV-2 &#40;COVID19&#41; pandemic and what the disease is.</p>
<p><strong>Keywords:</strong> ##summary ##health #covid19 #publichealth #pandemic #globalhealth #health #healthcare  #archive</p>
<h1>Bibliography</h1>
<p>Not Available</p>
<h1>Table of Contents</h1>
<div class="franklin-toc"><ol><li><ol><li>What is SARS-CoV-2?<ol><li>Symptoms</li><li><a href="https://jacobzelko.com/03102020052237-covid19-dying"><strong>Risk of dying:</strong></a></li><li><a href="https://jacobzelko.com/03102020053006-cdc-respiratory-preventions"><strong>Prevention Methods:</strong></a></li></ol></li></ol></li><li>How To Cite</li><li>References</li><li>Discussion: </li></ol></div>
<h3 id="what_is_sars-cov-2">What is SARS-CoV-2?</h3>
<p>The SARS-CoV-2 virus is a <a href="https://jacobzelko.com/03102020054429-coronavirus-definition">betacoronavirus</a>, like MERS-CoV and SARS-CoV. All three of these viruses have their origins in bats. The sequences from U.S. patients are similar to the one that China initially posted, suggesting a likely single, recent emergence of this virus from an animal reservoir.</p>
<p>Early on, many of the patients at the epicenter of the outbreak in Wuhan, Hubei Province, China had some link to a large seafood and live animal market, suggesting animal-to-person spread. Later, a growing number of patients reportedly did not have exposure to animal markets, indicating person-to-person spread. Person-to-person spread was subsequently reported outside Hubei and in countries outside China, including in the United States. &#91;1&#93;</p>
<p>Currently, the World Health Organization has not classified this situation as a pandemic though this stance is highly contentious. &#91;2&#93;</p>
<p>UPDATE &#40;MARCH 11th&#41;:_ As of now, this situation is now classified a pandemic by the World Health Organization. &#91;3&#93;</p>
<p>Here is an image showing its transmission across the world:</p>
<p><img src="https://jacobzelko.com/03102020050115-covid19-jhu-arcgis.jpg" alt="arcgis-sars" /></p>
<h4 id="symptoms">Symptoms</h4>
<p>The following symptoms may appear 2-14 days after exposure &#40;this is based on what has been seen previously as the incubation period of MERS-CoV viruses &#91;Middle East Respiratory Syndrome Coronavirus&#93;&#41; &#91;4&#93;:</p>
<ul>
<li><p>Fever</p>
</li>
<li><p>Cough</p>
</li>
<li><p>Shortness of breath</p>
</li>
</ul>
<h4 id="a_href03102020052237-covid19-dyingrisk_of_dying"><a href="https://jacobzelko.com/03102020052237-covid19-dying"><strong>Risk of dying:</strong></a></h4>
<p>1 - 2&#37; is the current estimate though it could get higher. &#91;5&#93;</p>
<h4 id="a_href03102020053006-cdc-respiratory-preventionsprevention_methods"><a href="https://jacobzelko.com/03102020053006-cdc-respiratory-preventions"><strong>Prevention Methods:</strong></a></h4>
<ul>
<li><p>Avoid close contact with people who are sick.</p>
</li>
<li><p>Avoid touching your eyes, nose, and mouth.</p>
</li>
<li><p>Stay home when you are sick.</p>
</li>
<li><p>Cover your cough or sneeze with a tissue, then throw the tissue in the trash.</p>
</li>
<li><p>Clean and disinfect frequently touched objects and surfaces using a regular household cleaning spray or wipe.</p>
</li>
<li><p>Wash your hands often with soap and water for at least 20 seconds, especially after going to the bathroom; before eating; and after blowing your nose, coughing, or sneezing.</p>
</li>
<li><p>If soap and water are not readily available, use an alcohol-based hand sanitizer with at least 60&#37; alcohol. Always wash hands with soap and water if hands are visibly dirty.</p>
</li>
</ul>
<p>&#91;6&#93;</p>
<h2 id="how_to_cite">How To Cite</h2>
<p>Zelko, Jacob. <em>SARS-CoV-2</em>. <a href="https://jacobzelko.com/03102020051547-sars-cov-2">https://jacobzelko.com/03102020051547-sars-cov-2</a>. March 10 2020.</p>
<h2 id="references">References</h2>
<p>&#91;1&#93; CDC and CDC, “Coronavirus Disease 2019 &#40;COVID-19&#41; Situation Summary,” 09-Mar-2020. &#91;Online&#93;. Available: https://www.cdc.gov/coronavirus/2019-ncov/summary.html. &#91;Accessed: 10-Mar-2020&#93;.</p>
<p>&#91;2&#93; “Statement on the second meeting of the International Health Regulations &#40;2005&#41; Emergency Committee regarding the outbreak of novel coronavirus &#40;2019-nCoV&#41;.” &#91;Online&#93;. Available: https://www.who.int/news-room/detail/30-01-2020-statement-on-the-second-meeting-of-the-international-health-regulations-&#40;2005&#41;-emergency-committee-regarding-the-outbreak-of-novel-coronavirus-&#40;2019-ncov&#41;. &#91;Accessed: 10-Mar-2020&#93;.</p>
<p>&#91;3&#93; “WHO Director-General’s opening remarks at the media briefing on COVID-19 - 11 March 2020.” &#91;Online&#93;. Available: https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19–-11-march-2020. &#91;Accessed: 15-Mar-2020&#93;.</p>
<p>&#91;4&#93; CDC and CDC, “Coronavirus Disease 2019 &#40;COVID-19&#41; – Symptoms,” 29-Feb-2020. &#91;Online&#93;. Available: https://www.cdc.gov/coronavirus/2019-ncov/about/symptoms.html. &#91;Accessed: 10-Mar-2020&#93;.</p>
<p>&#91;5&#93; M. Lipsitch, “Opinion | Why it’s so hard to pin down the risk of dying from coronavirus.” &#91;Online&#93;. Available: https://www.washingtonpost.com/opinions/2020/03/06/why-its-so-hard-pin-down-risk-dying-coronavirus/. &#91;Accessed: 10-Mar-2020&#93;.</p>
<p>&#91;6&#93; CDC and CDC, “Coronavirus Disease 2019 &#40;COVID-19&#41; – Prevention &amp; Treatment,” 15-Feb-2020. &#91;Online&#93;. Available: https://www.cdc.gov/coronavirus/2019-ncov/about/prevention-treatment.html. &#91;Accessed: 10-Mar-2020&#93;.</p>
<h2 id="discussion">Discussion: </h2>
<script src="https://giscus.app/client.js"
    data-repo="TheCedarPrince/thecedarprince.github.io"
    data-repo-id="R_kgDOHRFrHA"
    data-category="General"
    data-category-id="DIC_kwDOHRFrHM4CPGIX"
    data-mapping="url"
    data-reactions-enabled="1"
    data-emit-metadata="0"
    data-input-position="top"
    data-theme="dark_dimmed"
    data-lang="en"
    data-loading="lazy"
    crossorigin="anonymous"
    async>
</script>
 ]]>
  </content:encoded>
    
  <pubDate>Tue, 10 Mar 2020 00:00:00 +0000</pubDate>  
  
  
  <atom:author>
    <atom:name>Jacob Zelko</atom:name>
  </atom:author>
        
</item>

<item>
  <title>
    <![CDATA[  Risk of Dying from COVID19  ]]>
  </title>
  <link> https://jacobzelko.com/03102020052237-covid19-dying/index.html </link>
  <guid> https://jacobzelko.com/03102020052237-covid19-dying/index.html </guid>
  <description>
    <![CDATA[  Note on the current fatality when acquiring COVID19.  ]]>
  </description>  
  
  <content:encoded>
    <![CDATA[  
<h1>Risk of Dying from COVID19</h1>
<p><strong>Date:</strong> March 10 2020</p>
<p><strong>Summary:</strong> Note on the current fatality when acquiring COVID19.</p>
<p><strong>Keywords:</strong> ##zettel #covid19 #health #disease #epidemiology  #archive</p>
<h1>Bibliography</h1>
<p>Not Available</p>
<h1>Table of Contents</h1>
<div class="franklin-toc"><ol><li>How To Cite</li><li>References</li><li>Discussion: </li></ol></div>
<p>Several estimates have suggested that the risk of dying, for those infected with covid-19 and showing its flu-like symptoms, is around 1 or 2 percent. Elderly adults have a considerably higher risk of both becoming infected and dying, as do people with compromised immune systems. The estimates might change as new data arrive, but the range of 1 to 2 percent for fatalities among the symptomatic seems to be the consensus for now. The overall fatality rate for people infected with covid-19 will be lower &quot;possibly much lower&quot; when we know how many people are infected but asymptomatic.</p>
<blockquote>
<p><em>Marc Lipsitch is a professor of epidemiology and director of the Center for Communicable Disease Dynamics at Harvard T.H. Chan School of Public Health.</em></p>
</blockquote>
<h2 id="how_to_cite">How To Cite</h2>
<p>Zelko, Jacob. <em>Risk of Dying from COVID19</em>. <a href="https://jacobzelko.com/03102020052237-covid19-dying">https://jacobzelko.com/03102020052237-covid19-dying</a>. March 10 2020.</p>
<h2 id="references">References</h2>
<h2 id="discussion">Discussion: </h2>
<script src="https://giscus.app/client.js"
    data-repo="TheCedarPrince/thecedarprince.github.io"
    data-repo-id="R_kgDOHRFrHA"
    data-category="General"
    data-category-id="DIC_kwDOHRFrHM4CPGIX"
    data-mapping="url"
    data-reactions-enabled="1"
    data-emit-metadata="0"
    data-input-position="top"
    data-theme="dark_dimmed"
    data-lang="en"
    data-loading="lazy"
    crossorigin="anonymous"
    async>
</script>
 ]]>
  </content:encoded>
    
  <pubDate>Tue, 10 Mar 2020 00:00:00 +0000</pubDate>  
  
  
  <atom:author>
    <atom:name>Jacob Zelko</atom:name>
  </atom:author>
        
</item>
</channel></rss>